Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis. The US biotech has just ...
📄 This paper has been accepted to the IEEE Robotics and Automation Letters (RA-L) and will be presented at ICRA 2025. In industrial scenarios, effective human-robot collaboration relies on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results